Axogen forecasts at least $290M 2026 revenue, adds $7M from BioCircuit while planning prostate market development in 2027 (NASDAQ:AXGN)
· seekingalpha.com
Axogen Q3 2026 earnings: revenue jumped 26%, guidance rose to $290M, and BioCircuit adds NerveTape growth potential.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...